MaryAnn Go
Genentech
10 Papers
1 Citations
MaryAnn Go is an academic researcher from Genentech. The author has contributed to research in topics: Antibody-drug conjugate & Medicine. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates
Leanna Staben,Stefan G. Koenig,Sophie M. Lehar,Richard Vandlen,Donglu Zhang,Josefa Chuh,Shang-Fan Yu,Carl Ng,Jun Guo,Yanzhou Liu,Aimee Fourie-O'Donohue,MaryAnn Go,Xin Linghu,Nathaniel L. Segraves,Tao Wang,Jinhua Chen,Binqing Wei,Gail Lewis Phillips,Keyang Xu,Katherine R. Kozak,Sanjeev Mariathasan,John A. Flygare,Thomas H. Pillow +22 more
TL;DR: A bioreversible linkage based on a quaternary ammonium that can be used to connect a broad array of tertiary and heteroaryl amines to a carrier protein and shows the utility with both protease-cleavable and reductively cleavable antibody-drug conjugates.
122
Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
Elisabeth A. Lasater,Dhara N. Amin,Rajat Bannerji,Raghuveer Singh Mali,Kathy Barrett,Ryan N Rys,Jason Oeh,Eva Lin,Tim Sterne-Weiler,Ellen Ingalla,MaryAnn Go,Shang-Fan Yu,Maxwell M. Krem,Christopher Arthur,Uwe Hahn,Anna Johnston,Vinit Karur,Nadia Khan,Paula Marlton,Tycel Phillips,Giuseppe Gritti,John F. Seymour,Monica Tani,Sam Yuen,Scott E. Martin,Matthew T. Chang,Christopher M. Rose,Victoria Pham,Andrew Polson,Claudia M Wever,Nathalie A. Johnson,Jiang Yanwen,Jamie Hirata,Deepak Sampath,L. Musick,Christopher R. Flowers,Ingrid E. Wertz +36 more
TL;DR: In this paper , the authors identify the pro-survival BCL-2 protein family member MCL-1 as a resistance factor for the BCL•2 inhibitor venetoclax in non-Hodgkin lymphoma (NHL) cell lines and primary NHL samples.
16
Abstract 4634: Anthracycline based antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin's lymphoma are effective in cell lines resistant to auristatin based ADCs.
Andrew Polson,Bing Zheng,MaryAnn Go,Jeffery Lau,Shang-Fan Yu,Susan D. Spencer,Robert L. Cohen,Michele Caruso,John A. Flygare,Paul Polakis +9 more
TL;DR: Two cell lines that were resistant to anti-CD22-MC-vc-PAB-MMAE by consistently treating xenograft models with increase amounts of ADC are developed and suggest the resistance was not target related and CD22 expression was maintained in the resistant cell lines.
1
A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Shang-Fan Yu,Bing Zheng,MaryAnn Go,Jeff Lau,Susan D. Spencer,Helga Raab,Robert Soriano,Suchit Jhunjhunwala,Robert L. Cohen,Michele Caruso,Paul Polakis,John A. Flygare,Andrew Polson +12 more
TL;DR: These studies provide proof of concept for an anthracycline-based ADC that could be used to treat B-cell malignancies that are resistant to vc-MMAE–based conjugates.
Development of T-cell engagers selective for cells co-expressing two antigens
Daniel DiCara,Sunil Bhakta,MaryAnn Go,James Ziai,Ron Firestein,Bill Forrest,Chenlu Gu,Steven R. Leong,Genee Y. Lee,Shang-Fan Yu,Andrew Polson,Nicholas J. Agard +11 more
TL;DR: The development of TCEs that preferentially drive T cell-mediated death against target cells co-expressing two tumor-associated antigens are described, highlighting the potential for dual-antigen targeting to improve safety and efficacy, and expanding the scope of tumors that may effectively be treated by T CEs.